ROIV
Roivant Sciences Ltd.
There isn't enough reported data to score ROIV yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
ROIV Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Under pressure | |
| Strong |
ROIV's revenue and balance sheet are currently strong, but its profitability and cash flow are under pressure.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
ROIV PE Valuation
ROIV has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
ROIV Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ROIV's revenue to grow, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
ROIV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.57 | -$0.02 |
| Q2 2026 | -$0.47 | +$0.22 |
| Q1 2026 | -$0.54 | -$0.30 |
| Q4 2025 | -$1.16 | -$1.02 |
| Q3 2025 | -$0.55 | -110% |
| Q2 2025 | -$0.69 | -112% |
| Q1 2025 | -$0.24 | -105% |
| Q4 2024 | -$0.14 | -103% |
ROIV is still losing money, but far less than before: $0.57 per share over the past year, against $1.55 at its worst in late 2022.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over ROIV on earnings quality, reporting a profit while its opponent remains loss making.
ROIV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $35.1M | +2136% |
| Q2 2026 | $1.4M | -34% |
| Q1 2026 | $2.5M | -67% |
| Q4 2025 | $2M | -78% |
| Q3 2025 | $1.6M | -65% |
| Q2 2025 | $2.2M | -96% |
| Q1 2025 | $7.6M | -74% |
| Q4 2024 | $9M | -76% |
ROIV's revenue is recovering but still below its 2024 peak: $35M last quarter, up 2136% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -763% | +18730 points |
| Q2 2026 | -25381% | -12251 points |
| Q1 2026 | 16478% | +20242 points |
| Q4 2025 | -16966% | -13924 points |
| Q3 2025 | -19493% | -11857 points |
| Q2 2025 | -13130% | -12912 points |
| Q1 2025 | -3764% | -2845 points |
| Q4 2024 | -3043% | -16669 points |
ROIV's operating margin was −763% last quarter, up 18730 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over ROIV on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over ROIV on profitability, with a higher operating margin.
ROIV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $594.2M | +$787.7M |
| Q2 2026 | -$270.9M | -$62.5M |
| Q1 2026 | -$165.1M | +$8.3M |
| Q4 2025 | -$191.5M | +$17.5M |
| Q3 2025 | -$193.5M | +$74.3M |
| Q2 2025 | -$208.4M | -$14.6M |
| Q1 2025 | -$173.4M | -$64.6M |
| Q4 2024 | -$209.1M | +$1.7M |
ROIV has burned cash in almost every quarter: −$33M over the past year, against −$784M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over ROIV on cash generation, producing positive trailing cash flow while its opponent burns cash.
ROIV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +2M shares |
| 1 year | +6.1% | +41.8M shares |
| 3 years | -6.2% | -47.5M shares |
| 5 years | +11% | +72.5M shares |
ROIV has 723M diluted shares, up 6.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $74.5M |
| Q2 2026 | $206.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $208.3M |
| Q1 2025 | $295.4M |
| Q4 2024 | $243.3M |
| Q3 2024 | $106.1M |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over ROIV on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
ROIV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2024 | -0.5x | Net Cash |
| Q2 2024 | -1.2x | Net Cash |
| Q1 2024 | -1.4x | Net Cash |
| Q4 2023 | -1.5x | Net Cash |
ROIV has more cash than debt.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
ROIV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.8 | Neutral |
| Stochastic | 60.6 | Neutral |
ROIV's weekly RSI is 65 (neutral) and its Stochastic is 61 (neutral).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
ROIV PE vs Healthcare Sector
| Metric | ROIV | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ROIV has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
ROIV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $36.6 | 9.3% above |
| 20 week MA | $36.3 | 10% above |
| 50 week MA | $30.6 | 31% above |
| 100 week MA | $21.6 | 85% above |
| 200 week MA | $16.0 | 149% above |
ROIV has the edge over UNH on trend strength, trading above more of its moving averages.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 9.3% below its 200-week average.
ROIV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.92 | $10.1 | +1.8% |
| 2021 | $10.1 | $12.0 | +18% |
| 2022 | $12.0 | $7.01 | -41% |
| 2023 | $7.01 | $11.2 | +60% |
| 2024 | $11.2 | $11.8 | +5.1% |
| 2025 | $11.8 | $22.2 | +88% |
| 2026 YTD | $22.2 | $40.0 | +80% |
ROIV has the edge over UNH on returns for 2026, with the stronger performance.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has finished three years in a row lower, and it's up 22% so far in 2026.